McKesson completes US Oncology purchase for $2.2B

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
McKesson, a healthcare services and IT company, has completed its acquisition of US Oncology in a total transaction, including the assumption or repayment of the outstanding debt of US Oncology and its subsidiaries, which was valued at approximately $2.2 billion.

With the completion of the acquisition, initially announced Nov. 1, McKesson now delivers a set of oncology practice management offerings in the U.S. to help strengthen the financial performance of community oncologists and advance cancer care. According to the San Francisco-based company, oncologists will select from products and services, such as specialty distribution or inventory management technologies, or choose to become a strategic alliance customer, which provides technologies, practice management services and other resources for community oncologists.

The combined business will be led by Bruce Broussard, CEO of US Oncology, and will be headquartered in Woodlands, Texas, with continuing operations in the San Francisco Bay area and other locations throughout the U.S. Broussard now reports to Paul Julian, executive vice president and group president at McKesson.

 

Justine Varieur Cadet

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.